Amycretin amycretin PHASE2
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Peak Sales Est$12000M
Formulations[]
Companies
NVO (ORIGINATOR)100%
Mechanism: GLP-1/Amylin dual agonist
Expert: Dual agonist targeting both GLP-1 and amylin receptors, providing synergistic effects on satiety, gastric emptying, and glucose homeostasis through complementary central and peripheral mechanisms.
Everyday: Combines two hormones that work together to reduce appetite and blood sugar more effectively than either alone.
Targets: ["GLP-1","AMYLIN"]
Programs (2)
IndicationStageKey StudyRegional Status
ObesityPHASE3Phase 3 program[]
Type 2 DiabetesPHASE3Phase 3 program[]
Upcoming Catalysts (2)
Amycretin - Obesity - Ph3 - Start Q1 2026
Amycretin - T2D - Ph3 - Start 2026
Notes
Unimolecular GLP-1/amylin agonist. Phase 2 showed 22% weight loss. Phase 3 starting Q1 2026 for obesity and T2D. Both SC and oral formulations in development.
Data from Supabase · Updated 2026-03-24